

BlueOcean NutraSciences Announces a Shrimp Oil Pilot Encapsulation Trial with a European Customer and Order Expectations

TORONTO, ONTARIO—(April 2016) – BlueOcean NutraSciences (TSX VENTURE:BOC) (“BlueOcean” or the “Company”), a nutraceutical Company developing specialty oils and extended release (XR) Omega-3 tablets from shrimp, fish, krill and algae oil for Health and Wellness markets, is pleased to announce that it has begun a pilot encapsulation trial with a European Customer (“Customer”) using the Company’s bulk Northern AstaShrimp oil. The Customer has identified Northern AstaShrimp oil as a key ingredient in a unique formulation consisting of other key nutrients in the final product. This is due to Northern AstaShrimp having high levels of esterified natural astaxanthin, phospholipids and omega-3 EPA/DHA.

Following the pilot encapsulation trial, the Company expects an order from the Customer for up to 200 kg of bulk Northern AstaShrimp oil. This order is expected to be the first of larger annual orders that will be received in time for the beginning of the May to October Newfoundland Northern cold water shrimp season.

The European Customer has also reached the final stage of EU regulatory approval for Northern AstaShrimp oil sales. The European omega-3 market represents over 20% of global omega-3 sales, with the European supplements category valued at \$1Bn.

BlueOcean CEO, Gavin Bogle, said of the trial, “Many bulk customers require a small encapsulation trial to make sure the shrimp oil works in their equipment prior to placing a larger bulk order. We have already conducted our own encapsulation trials and run six month accelerated stability trials on the soft gels. The results were very good with the soft gels maintaining good form and the essential parameters being stable. We are starting to gain momentum in our sales efforts and are looking forward to closing these bulk orders soon after the trials complete, just in time for the start of the Northern shrimp season in May.”

About BlueOcean NutraSciences:

BlueOcean NutraSciences Inc. is a Canadian listed public Company (TSX VENTURE:BOC) that is focused on developing sustainable, specialty nutraceutical oil products targeted at the rapidly growing Natural Astaxanthin, Omega-3 and Algal oil health and wellness markets. BlueOcean’s bulk shrimp oils contain high levels of naturally occurring astaxanthin, phospholipids, and omega-3 EPA and DHA. Northern and Pacific AstaShrimp™ bulk oils are targeted at the high value and rapidly growing natural astaxanthin and phospholipid omega-3 markets.

BlueOcean and its JV partner, CMAX technologies, have developed a process to convert shrimp, krill, algae and other fish oils into Extended Release Tablets. BlueOcean owns 50% of the participating and voting rights in 2453969 Ontario Inc., a joint venture with CMAX Technologies that has developed the extended release omega-3/astaxanthin tablets. 2453969 Ontario Inc. also has a 66.7% ownership in Pure Polar Labs Inc., a Nevada company that sells omega-3 and astaxanthin retail products under the brand Pure Polar.

BlueOcean’s Pure Polar™ Omega-3 Shrimp Oil formulations contain over two times more omega-3 EPA & DHA and 10 times more astaxanthin than typical retail krill oil brands, and contain phospholipids for better absorption of omega-3s. Product details and ordering can be

found at:

www.purepolarshrimp.com, Amazon.com, Inboxfitness.com and Bonanza.com

Forward Looking Statements: BlueOcean

This news release may contain forward-looking statements that are based on BlueOcean's expectations, estimates and projections regarding its business and the economic environment in which it operates. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to control or predict. Therefore, actual outcomes and results may differ materially from those expressed in these forward-looking statements and readers should not place undue reliance on such statements. Statements speak only as of the date on which they are made, and the Company undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances, unless otherwise required to do so by law.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

BlueOcean NutraSciences Inc.

Gavin Bogle

CEO

416-970-3266

BlueOcean NutraSciences Inc.

Dil Vashi

Director of Corporate Development

416-859-0909

www.blueoceannutra.ca